CL2023003731A1 - Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2- metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6- diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer - Google Patents
Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2- metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6- diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncerInfo
- Publication number
- CL2023003731A1 CL2023003731A1 CL2023003731A CL2023003731A CL2023003731A1 CL 2023003731 A1 CL2023003731 A1 CL 2023003731A1 CL 2023003731 A CL2023003731 A CL 2023003731A CL 2023003731 A CL2023003731 A CL 2023003731A CL 2023003731 A1 CL2023003731 A1 CL 2023003731A1
- Authority
- CL
- Chile
- Prior art keywords
- methylhexan
- diazaspiro
- octan
- triazin
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021100466 | 2021-06-17 | ||
| CN2022091677 | 2022-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003731A1 true CL2023003731A1 (es) | 2024-07-05 |
Family
ID=82196389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003731A CL2023003731A1 (es) | 2021-06-17 | 2023-12-13 | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2- metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6- diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
| KR20260099138A (ko) | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| KR20260115654A (ko) | 2023-12-04 | 2026-07-24 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | 치환된 다환 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー,インク. | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
-
2022
- 2022-06-16 AU AU2022292697A patent/AU2022292697A1/en active Pending
- 2022-06-16 KR KR1020237043027A patent/KR20240021808A/ko active Pending
- 2022-06-16 MX MX2023014890A patent/MX2023014890A/es unknown
- 2022-06-16 EP EP22733288.9A patent/EP4355747A1/en active Pending
- 2022-06-16 CN CN202280043068.0A patent/CN117597348A/zh active Pending
- 2022-06-16 JP JP2023576415A patent/JP7864745B2/ja active Active
- 2022-06-16 CA CA3220099A patent/CA3220099A1/en active Pending
- 2022-06-16 CN CN202410890382.3A patent/CN118852178A/zh active Pending
- 2022-06-16 PE PE2023003361A patent/PE20240923A1/es unknown
- 2022-06-16 WO PCT/CN2022/099089 patent/WO2022262796A1/en not_active Ceased
- 2022-06-16 PH PH1/2023/553300A patent/PH12023553300A1/en unknown
- 2022-06-16 US US18/570,727 patent/US20260125387A1/en active Pending
- 2022-06-16 IL IL309359A patent/IL309359A/en unknown
- 2022-06-17 UY UY0001039823A patent/UY39823A/es unknown
-
2023
- 2023-11-28 DO DO2023000260A patent/DOP2023000260A/es unknown
- 2023-12-13 CL CL2023003731A patent/CL2023003731A1/es unknown
- 2023-12-28 CO CONC2023/0018577A patent/CO2023018577A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202315636A (zh) | 2023-04-16 |
| WO2022262796A1 (en) | 2022-12-22 |
| KR20240021808A (ko) | 2024-02-19 |
| PH12023553300A1 (en) | 2024-04-08 |
| IL309359A (en) | 2024-02-01 |
| CO2023018577A2 (es) | 2024-01-15 |
| UY39823A (es) | 2023-01-31 |
| JP7864745B2 (ja) | 2026-05-25 |
| MX2023014890A (es) | 2024-04-29 |
| AU2022292697A1 (en) | 2024-02-01 |
| US20260125387A1 (en) | 2026-05-07 |
| CN117597348A (zh) | 2024-02-23 |
| WO2022262796A8 (en) | 2023-03-23 |
| JP2024525145A (ja) | 2024-07-10 |
| CN118852178A (zh) | 2024-10-29 |
| DOP2023000260A (es) | 2024-05-15 |
| CA3220099A1 (en) | 2022-12-22 |
| EP4355747A1 (en) | 2024-04-24 |
| PE20240923A1 (es) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023018577A2 (es) | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer | |
| CL2023001530A1 (es) | Derivados espiráncos sustituidos de cadena lineal | |
| CL2023003531A1 (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. | |
| UY38742A (es) | Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida | |
| UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| CL2011000880A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer. | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| AR012488A1 (es) | Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion | |
| CO6420344A2 (es) | Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map) | |
| EP1749830A4 (en) | CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS | |
| MX2023013174A (es) | Derivados espiro sustituidos. | |
| MX2023013176A (es) | Derivados espiro sustituidos. | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| BR0308182A (pt) | Agentes org²nicos de cobre biologicamente ativos | |
| AR042687A1 (es) | Pirimidinas sustituidas y su uso como inhibidores de mmp-13 selectivos. procedimiento de preparacion y composiciones farmaceuticas. | |
| BR112023025436A2 (pt) | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas | |
| AR063819A1 (es) | Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos. | |
| AR037140A1 (es) | Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende | |
| AR037586A1 (es) | Antagonistas vii de los receptores ccr-3 | |
| ES2060675T3 (es) | Imidazobenzodiacepina eficaz como antipsicotico. | |
| AR120802A1 (es) | Derivados espiráncos sustituidos de cadena lineal | |
| ECSP982734A (es) | Inhibidores de aminotiazol de ciclinas dependientes de cinasas | |
| ECSP993092A (es) | Tripeptidos inhibidores de la hepatitis c |